Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Nanosonics (ASX:NAN): A disinfection company turning itself around and has gained 50% so far in 2025

Nanosonics (ASX:NAN) was in the best space to be during the pandemic - disinfection technology. Its flagship Trophon machines are electron paramagnetic resonance (EPR) devices aimed to reduce cross contamination in hospitals and other healthcare settings, particularly through ultrasound probes which have conventionally been hand-wiped. Source: Company The company has over 30,000 of these deployed worldwide and…

ByNick SundichFebruary 25, 2025

Medigrowth delivers on its 2023 capital raising

It's been a great couple of years for the Melbourne-based medicinal cannabis company Medigrowth Australia Pty Ltd. Back in mid-2023, Medigrowth raised $3.2m in new capital on the Australian crowd-funding platform Birchal. The company had generated just under $1m in revenue in the previous twelve months, but average monthly sales were growing at 20-30% p.a.,…

ByNick SundichFebruary 24, 2025

How can you find the best stocks for retirement? It starts with looking at these 4 sectors

In this article, we ask the question: how can you find the best stocks for retirement? Investing in stocks can be a great way to build wealth for retirement. However, not all stock sectors are suitable for investors investing for retirement. We think there are 4 that are best suited for retirees. Best stocks for retirement Generally,…

ByNick SundichFebruary 24, 2025

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Recce Pharmaceuticals (ASX:RCE) has completed its Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections) for RECCE® 327 Topical Gel (R327G) and released the results earlier this week. The results were positive, and pave the way for commercialisation as early as 2026. How Recce got to this point Recce is a biotech company focused…

ByNick SundichFebruary 19, 2025

Chemist Warehouse is now ASX listed! Here are 5 critical things all investors need to know!

Chemist Warehouse is now ASX listed - 14 months since the plan to list was first unveiled. Australia's largest pharmacy chain had long been mulled as an IPO candidate. But - with IPO conditions less than ideal - it chose to list via a reverse takeover of Sigma Healthcare (ASX:SIG). The irony is that despite…

ByNick SundichFebruary 14, 2025

Alterity Therapeutics (ASX:ATH) more than doubled after its Phase 2 results, but its still only $80m

Alterity Therapeutics (ASX:ATH) hit the jackpot last week. Any clinical-stage biotech achieving a positive Phase 2 outcome is good news, because it depicts that the company's drug is not just safe, but that it works too. But while some companies (like Paradigm (ASX:PAR)) are going after markets with existing drugs that need replacement, Alterity is…

ByNick SundichFebruary 3, 2025

Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025

Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate sodum (PPS) (now known as Zilosul) to market. It is still a couple of years away, but is about to make a major step towards this goal in starting a Phase 3 trial. And we…

ByNick SundichJanuary 23, 2025

Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them

There aren't many ASX stocks fighting diabetes, but the few that are have a big market opportunity ahead of them. And they are not just about fighting the condition directly but other ailments that can result from having diabetes. It is estimated that 537m people have diabetes globally and 3 out of 4 of them live in…

ByNick SundichJanuary 21, 2025

The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!

Here Are Our 5 Top ASX Health Stocks for 2025! Avita Medical (ASX:AVH) OK, first thing's first. We know this ASX health stock fell 14% on January 8 after it announced a revenue downgrade for Q4. But the past is the past. The company told investors to expect $100-106m revenue in CY25, 55-65% above…

ByNick SundichJanuary 10, 2025

Here are our 6 Best ASX Stocks for 2025 and why you should give them a look!

Here are our 6 Best ASX Stocks for 2025! Opthea (ASX:OPT) Its been a long wait, but 2025 will finally be the year Opthea (ASX:OPT) investors receive Phase 3 results. Opthea is an optometry biotech developing Sozinibercept - a drug fighting wet AMD. Wet AMD is the leading cause of blindness, impacting 3.5m people annually…

ByNick SundichDecember 27, 2024

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Nanosonics (ASX:NAN): A disinfection company turning itself around and has gained 50% so far in 2025

Medigrowth delivers on its 2023 capital raising

How can you find the best stocks for retirement? It starts with looking at these 4 sectors

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Chemist Warehouse is now ASX listed! Here are 5 critical things all investors need to know!

Alterity Therapeutics (ASX:ATH) more than doubled after its Phase 2 results, but its still only $80m

Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025

Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them

The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!

Here are our 6 Best ASX Stocks for 2025 and why you should give them a look!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here